RecruitingPhase 2NCT06857955

A Study to Identify an Optimal Dose of QCZ484 in Mild to Moderate Hypertensive Patients

A Randomized, Double-blind, Placebo-controlled, Multicenter, 12 Months Treatment Duration, Dose Finding Study, to Evaluate Efficacy, Safety and Pharmacodynamics of QCZ484 in Mild to Moderate Hypertensive Patients

Sponsor

Novartis Pharmaceuticals

Enrollment

380 participants

Start Date

Mar 26, 2025

Study Type

INTERVENTIONAL

Conditions

Hypertension

Summary

The purpose of this study is to evaluate the efficacy, safety and tolerability of QCZ484 or placebo, given subcutaneously, every 6 months, at different dose levels in patients with mild to moderate hypertension

Eligibility

Min Age: 18 YearsMax Age: 75 Years

Plain Language Summary

Simplified for easier understanding

This study is finding the right dose of a new experimental blood pressure medication called QCZ484 for patients with mild to moderate high blood pressure, comparing it against existing treatments to assess safety and effectiveness. **You may be eligible if...** - You are aged 18–75 (male or female) - You have been diagnosed with high blood pressure (hypertension) - You are either on no current blood pressure medication, or on no more than 2 medications that can be safely stopped for 4 weeks before the study - Your blood pressure readings meet specific thresholds measured by two different methods **You may NOT be eligible if...** - You have a known cause of high blood pressure other than essential hypertension (e.g., kidney artery disease) - You have orthostatic hypotension (blood pressure drops when you stand) - You have liver disease, heart failure, a history of heart attack, or significant heart rhythm problems - You have intolerance to ACE inhibitors or ARB drugs (a common type of blood pressure medication) Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERSaline

0.9% sodium chloride saline solution

DRUGQCZ484

Solution of Injection

Locations(84)

SEC Clinical Research LLC

Andalusia, Alabama, United States

UAB St Vincents

Birmingham, Alabama, United States

Longwood Research

Huntsville, Alabama, United States

The Center for Clinical Trials

Saraland, Alabama, United States

Elite Clinical Studies

Phoenix, Arizona, United States

Synexus Clinical Research US Inc

Tucson, Arizona, United States

NICRs Research Center

Garden Grove, California, United States

Valiance Clinical Research

Huntington Park, California, United States

Downtown L A Research Center Inc

Los Angeles, California, United States

Clinical Trials Research Sacramento

Sacramento, California, United States

Encompass Clinical Research

Spring Valley, California, United States

Clinical Research of Brandon LLC

Brandon, Florida, United States

ALL Medical Research LLC

Cooper City, Florida, United States

National Research Institute

Hialeah, Florida, United States

Cen Exel RCA

Hollywood, Florida, United States

East Coast Institute for Research

Jacksonville, Florida, United States

Entrust Clinical Research

Miami, Florida, United States

Inpatient Research Clinical LLC

Miami Lakes, Florida, United States

Inpatient Research Clinical LLC

Miami Lakes, Florida, United States

Suncoast Clinical Research

New Port Richey, Florida, United States

Renstar Medical Research

Ocala, Florida, United States

American Research Centers of FL

Pembroke Pines, Florida, United States

Cen Exel FCR

Tampa, Florida, United States

Cardiology Partners Clinical Research Institute

Wellington, Florida, United States

Centricity Research

Columbus, Georgia, United States

Javara Research

Fayetteville, Georgia, United States

Javara Research

Fayetteville, Georgia, United States

Velocity Clinical Research

Savannah, Georgia, United States

Solaris Clinical Research

Meridian, Idaho, United States

Cedar Crosse Research Ct

Chicago, Illinois, United States

Eagle Clinical Research

Chicago, Illinois, United States

Synexus Clinical Research US

Evansville, Indiana, United States

Velocity Clin Research Sioux City

Sioux City, Iowa, United States

Alliance for Multispecialty Research

Wichita, Kansas, United States

Velocity Clinical Res Baton Rouge

Baton Rouge, Louisiana, United States

Southern Clin Research Clinic

Zachary, Louisiana, United States

Ascension Saint Agnes Heart Care

Baltimore, Maryland, United States

Anderson Medical Research

Ft. Washington, Maryland, United States

Capitol Cardiology Associates

Lanham, Maryland, United States

AA Medical Research Center

Flint, Michigan, United States

Oakland Medical Research Center

Troy, Michigan, United States

Trinity Health Michigan Heart

Ypsilanti, Michigan, United States

Synexus Clinical Research US Inc

Richfield, Minnesota, United States

David M Headley Clinic

Port Gibson, Mississippi, United States

Healthcare Research Network II LLC

Hazelwood, Missouri, United States

Jefferson City Medical Group

Jefferson City, Missouri, United States

Clin Rsrch Consult a JCCT Company

Kansas City, Missouri, United States

Velocity Clin at Pioneer Heart Inst

Lincoln, Nebraska, United States

AMR Las Vegas

Las Vegas, Nevada, United States

CenExel HRI

Berlin, New Jersey, United States

Velocity Clinical Research

Binghamton, New York, United States

Novant Health Heart Vas Inst

Charlotte, North Carolina, United States

Monroe Biomedical Research

Monroe, North Carolina, United States

Burke Primary Care

Morganton, North Carolina, United States

Accellacare of Rocky Mount

Rocky Mount, North Carolina, United States

Accellacare of Salisbury

Salisbury, North Carolina, United States

CR Services Acquisition US

Columbus, Ohio, United States

Conrad Clinical Research

Edmond, Oklahoma, United States

Velocity Clinical Research Medford

Medford, Oregon, United States

TCV Clinical Studies

Linwood, Pennsylvania, United States

Velocity Clinical Research

Union, South Carolina, United States

Clinical Neuroscience Solutions Inc

Memphis, Tennessee, United States

Velocity Clinical Research Austin

Austin, Texas, United States

North Hills Medical Research Inc

Bedford, Texas, United States

Synergy Group Medical LLC

Houston, Texas, United States

Biopharma Informatic

Katy, Texas, United States

Synergy Groups Medical LLC

Missouri City, Texas, United States

Sun Research Institute

San Antonio, Texas, United States

Clinical Trials of Texas

San Antonio, Texas, United States

AMR Layton

Layton, Utah, United States

Manassas Clinical Research Center

Manassas, Virginia, United States

Dominion Medical Associates

Richmond, Virginia, United States

Centricity Research Suffolk Fam Med

Suffolk, Virginia, United States

MultiCare Ins Research Innovation

Puyallup, Washington, United States

Velocity Clinical Research Spokane

Spokane, Washington, United States

Novartis Investigative Site

Suita, Osaka, Japan

Novartis Investigative Site

Chuo Ku, Tokyo, Japan

Novartis Investigative Site

Chuo Ku, Tokyo, Japan

Novartis Investigative Site

Chuo-ku, Tokyo, Japan

Novartis Investigative Site

Shinjuku Ku, Tokyo, Japan

Novartis Investigative Site

Singapore, Singapore

Novartis Investigative Site

Singapore, Singapore

Novartis Investigative Site

Singapore, Singapore

Novartis Investigative Site

Singapore, Singapore

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06857955

Related Trials

Study of Efficacy and Safety of Tonlamarsen in Participants With Acute Severe Hypertension Recently Discharged From the Hospital

NCT075113614 locations

Genetics of Type 2 Diabetes in West Africans

NCT008371225 locations

A Study to Identify an Optimal Dose of QCZ484 in Mild to Moderate Hypertensive Patients

Conditions

Summary

Eligibility

Plain Language Summary

Interventions

Locations(84)

Related Trials

Clinical and Molecular Characteristics of Primary Aldosteronism in Blacks

Cardiac Effects of Mineralocorticoid Receptor Antagonism After Preeclampsia

Global Paradise System US Post Approval Study

Study of Efficacy and Safety of Tonlamarsen in Participants With Acute Severe Hypertension Recently Discharged From the Hospital

Genetics of Type 2 Diabetes in West Africans